N-(4-叔-丁基苯甲基)环丙胺 | 119290-83-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-叔-丁基苯甲基)环丙胺
• 英文名称: N-[(4-tert-butylphenyl)methyl]cyclopropanamine
• CAS: 119290-83-4
• 化学式: C₁₄H₂₁N
• mdl: MFCD09045000
• 分子量: 203.32
• InChiKey: WOEIDUGAOYDNPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN−PROTEIN INTERACTION<br/>[FR] INHIBITEURS À PETITES MOLÉCULES POUR L'INTERACTION PROTÉINE-PROTÉINE DE LYMPHOME À LYMPHOCYTES T/β-CATÉNINE
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2021055936A1

  公开（公告）日：2021-03-25

  Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/ E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.

  本文披露了β-连接蛋白/B细胞淋巴瘤9相互作用的抑制剂。这些抑制剂对β-连接蛋白/B细胞淋巴瘤9的选择性高于β-连接蛋白/E-钙粘蛋白PPI相互作用。还披露了使用这些披露的化合物来治疗癌症的方法。
• [EN] PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION<br/>[FR] PROCÉDÉ D'ÉLABORATION DE N-(BENZYL)CYCLOPROPANAMINES SUBSTITUÉS PAR HYDROGÉNATION D'IMINES
  申请人：BAYER CROPSCIENCE AG

  公开号：WO2012059585A1

  公开（公告）日：2012-05-10

  The present invention relates to a process for the preparation of substituted N-(benzyl)cyclopropanamines of the general formula (II) starting from N-[(aryl)methylene]cyclopropanamine derivatives. The present invention further provides the N-[(aryl)methylene]cyclopropanamine derivatives used as starting compounds in this process according to the invention, and their use for the preparation of substituted N-(benzyl)cyclopropanamines.

  本发明涉及一种从N-[(芳基)亚甲基]环丙胺衍生物出发制备取代N-(苄基)环丙胺的方法，其一般式为(II)。本发明还提供了用作本发明中所述方法的起始化合物的N-[(芳基)亚甲基]环丙胺衍生物，以及它们用于制备取代N-(苄基)环丙胺的用途。
• CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS
  申请人：Pulici Maurizio

  公开号：US20110118278A1

  公开（公告）日：2011-05-19

  There are provided bicyclic carbonylamino-pyrazoles of formula (I), wherein the variables are as specified in the claims, for use as medicament, in particular for the treatment of diseases due to the malfunctioning of protein kinases (PKs), such as cancer, pharmaceutical compositions comprising such carbamoyl derivatives, and their use as prodrugs of therapeutically active agents. Method of treatment and some new bicyclic carbonylamino-pyrazoles are also object of the present invention.

  本发明提供了式(I)的双环羰基氨基吡唑化合物，其中变量如权利要求中所述，用作药物，特别是用于治疗由蛋白激酶（PKs）功能失调引起的疾病，如癌症，包含此类羰酰基衍生物的制药组合物，并将其用作治疗活性剂的前药。本发明还涉及治疗方法和一些新的双环羰基氨基吡唑化合物。
• PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION
  申请人：Bayer CropScience AG

  公开号：EP2635551B1

  公开（公告）日：2018-05-02
• SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION
  申请人：H. Lee Moffitt Cancer Center and Research Institute, Inc.

  公开号：US20220411372A1

  公开（公告）日：2022-12-29

  Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.